Welcome to Markets Desk, here's what's moving the needle right now.
France is in the grip of serious civil unrest, as riot police struggle to contain widespread violence sweeping major cities. City halls, luxury boutiques, and public infrastructure have all been targeted, with French political leaders now trading blame rather than solutions. The instability carries real economic weight — tourism, retail, and investor confidence in the eurozone's second-largest economy are all under pressure.
Shifting to biotech, BioNTech has taken another blow after a second cancer vaccine candidate hit a significant clinical setback. The company has been racing to build a post-pandemic revenue base, and these failures make that transition harder. Investors are now questioning whether the pipeline is deep enough to justify current valuations, and BNTX shares face renewed scrutiny heading into the next earnings cycle.
And in cannabis, Trump's executive order directing marijuana rescheduling remains gridlocked inside the DEA, with no clear timeline for resolution. That bureaucratic stall is hitting companies like Canopy Growth hard, which had been pricing in regulatory progress. Until the DEA moves, the broader cannabis sector remains in a holding pattern — long on political promises, short on actual policy relief.
That's the tape. Markets Desk, signing off the floor.
